DE69633405D1 - Behandlung von prostatakrebs mit lhrh-antagonisten - Google Patents

Behandlung von prostatakrebs mit lhrh-antagonisten

Info

Publication number
DE69633405D1
DE69633405D1 DE69633405T DE69633405T DE69633405D1 DE 69633405 D1 DE69633405 D1 DE 69633405D1 DE 69633405 T DE69633405 T DE 69633405T DE 69633405 T DE69633405 T DE 69633405T DE 69633405 D1 DE69633405 D1 DE 69633405D1
Authority
DE
Germany
Prior art keywords
lhrh
methods
therapy
lhrh antagonist
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69633405T
Other languages
English (en)
Other versions
DE69633405T2 (de
Inventor
B Garnick
J Molineaux
L Gefter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praecis Pharmaceuticals Inc
Original Assignee
Praecis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24290700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69633405(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Praecis Pharmaceuticals Inc filed Critical Praecis Pharmaceuticals Inc
Publication of DE69633405D1 publication Critical patent/DE69633405D1/de
Application granted granted Critical
Publication of DE69633405T2 publication Critical patent/DE69633405T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
DE69633405T 1995-12-15 1996-11-25 Behandlung von prostatakrebs mit lhrh-antagonisten Expired - Fee Related DE69633405T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/573,109 US5780435A (en) 1995-12-15 1995-12-15 Methods for treating prostate cancer with LHRH-R antagonists
US573109 1995-12-15
PCT/US1996/018911 WO1997022357A1 (en) 1995-12-15 1996-11-25 Methods for treating prostate cancer with lhrh antagonists

Publications (2)

Publication Number Publication Date
DE69633405D1 true DE69633405D1 (de) 2004-10-21
DE69633405T2 DE69633405T2 (de) 2005-11-17

Family

ID=24290700

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633405T Expired - Fee Related DE69633405T2 (de) 1995-12-15 1996-11-25 Behandlung von prostatakrebs mit lhrh-antagonisten

Country Status (12)

Country Link
US (6) US5780435A (de)
EP (2) EP0871468B1 (de)
JP (2) JP4126094B2 (de)
AT (1) ATE275962T1 (de)
AU (1) AU730948B2 (de)
CA (1) CA2238993C (de)
DE (1) DE69633405T2 (de)
DK (1) DK0871468T3 (de)
ES (1) ES2227622T3 (de)
HK (1) HK1016087A1 (de)
PT (1) PT871468E (de)
WO (1) WO1997022357A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US5691314A (en) 1996-03-18 1997-11-25 The Medical College Of Hampton Roads Adjunctive therapy
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6217844B1 (en) * 1998-04-27 2001-04-17 Praecis Pharmaceuticals, Inc. Methods for detecting lesions in dense breast tissue using LHRH antagonists
AU6004999A (en) * 1998-10-08 2000-04-26 Takeda Chemical Industries Ltd. Agents for retarding change of hormone-dependent cancer into hormone-independentcancer
US6498181B1 (en) 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US7105560B1 (en) 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7129262B2 (en) * 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6428785B1 (en) 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
US7109171B2 (en) * 2000-02-28 2006-09-19 Praecis Pharmaceuticals Inc. Methods for treating FSH related conditions with GnRH antagonists
WO2002002144A1 (en) * 2000-07-05 2002-01-10 Takeda Chemical Industries, Ltd. Medicinal preparations for treating sex hormone-dependent diseases
JP2002080397A (ja) * 2000-07-05 2002-03-19 Takeda Chem Ind Ltd 性ホルモン依存性疾患の治療用医薬製剤
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
WO2002056903A2 (en) * 2001-01-17 2002-07-25 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
US20040248971A1 (en) * 2001-07-27 2004-12-09 Shuyuan Yeh Use of vitamin e succinate and antiandrogen combination
DE10137174A1 (de) * 2001-07-31 2003-02-13 Zentaris Ag Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
US20040138138A1 (en) * 2001-08-02 2004-07-15 Jurgen Engel Use of LHRH-antagonists in doses that do not cause castration for the improvement of T-cell mediated immunity
US6844014B1 (en) 2002-07-22 2005-01-18 Stephen Rafkin Herbal healing lotion for veterinary use
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
AU2003295336A1 (en) * 2002-09-19 2004-04-08 Dennis A. Carson Use of etodoclac to treat hyperplasia
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
WO2004056388A1 (en) * 2002-12-19 2004-07-08 Praecis Pharmaceuticals, Inc. Methods of enhancing immune system function in a subject
US20060217316A1 (en) * 2003-04-02 2006-09-28 Ragab El-Rashidy Method for the treatment of prostate cancer
JP4898431B2 (ja) * 2003-04-29 2012-03-14 ザ ジェネラル ホスピタル コーポレイション 複数薬物の持続放出のための方法およびデバイス
GB0320806D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
GB0403744D0 (en) * 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
US7918795B2 (en) 2005-02-02 2011-04-05 Gynesonics, Inc. Method and device for uterine fibroid treatment
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US10058342B2 (en) 2006-01-12 2018-08-28 Gynesonics, Inc. Devices and methods for treatment of tissue
US7874986B2 (en) 2006-04-20 2011-01-25 Gynesonics, Inc. Methods and devices for visualization and ablation of tissue
US7815571B2 (en) * 2006-04-20 2010-10-19 Gynesonics, Inc. Rigid delivery systems having inclined ultrasound and needle
US9357977B2 (en) * 2006-01-12 2016-06-07 Gynesonics, Inc. Interventional deployment and imaging system
US20070161905A1 (en) * 2006-01-12 2007-07-12 Gynesonics, Inc. Intrauterine ultrasound and method for use
US11259825B2 (en) 2006-01-12 2022-03-01 Gynesonics, Inc. Devices and methods for treatment of tissue
US8206300B2 (en) 2008-08-26 2012-06-26 Gynesonics, Inc. Ablation device with articulated imaging transducer
US10595819B2 (en) 2006-04-20 2020-03-24 Gynesonics, Inc. Ablation device with articulated imaging transducer
US20100056926A1 (en) * 2008-08-26 2010-03-04 Gynesonics, Inc. Ablation device with articulated imaging transducer
WO2008116141A1 (en) * 2007-03-21 2008-09-25 Emisphere Technologies, Inc. Allylqxy and alkyloxy benzoic acid delivery agents
US20090018486A1 (en) * 2007-07-13 2009-01-15 Menachem Goren Diagnosis and treatment of vericocele and prostate disorders
US20100204639A1 (en) * 2007-07-13 2010-08-12 Yigal Gat Diagnosis and treatment of varicocele and prostate disorders
CA2693735A1 (en) * 2007-07-13 2009-01-22 Yigal Gat Diagnosis and treatment of varicocele and prostate disorders
US8088072B2 (en) 2007-10-12 2012-01-03 Gynesonics, Inc. Methods and systems for controlled deployment of needles in tissue
US20090287081A1 (en) * 2008-04-29 2009-11-19 Gynesonics , Inc Submucosal fibroid ablation for the treatment of menorrhagia
US8262574B2 (en) 2009-02-27 2012-09-11 Gynesonics, Inc. Needle and tine deployment mechanism
CN110133299A (zh) * 2012-03-18 2019-08-16 株式会社资生堂 疾病样品分析装置、分析系统及分析方法
SG10201912719TA (en) 2012-09-26 2020-02-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CN107778354B (zh) * 2016-08-25 2021-03-02 成都圣诺生物制药有限公司 一种合成阿巴瑞克的方法
CN110290751B (zh) 2016-11-11 2022-11-22 杰尼索尼克斯公司 组织的受控治疗及与组织和/或治疗数据的动态交互和比较
EP3554526B1 (de) 2016-12-14 2024-05-08 Purdue Research Foundation Konjugate von hormonrezeptor mit freisetzung von luteinisierendem hormon (lhrh-r) und verwendungen davon
AU2018351714A1 (en) 2017-10-16 2020-04-30 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US5064813A (en) * 1984-08-02 1991-11-12 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US5023234A (en) * 1985-02-08 1991-06-11 Fernand Labrie Combination male breast cancer therapy
US5110904A (en) * 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
CA2062973C (en) * 1989-07-07 2003-09-23 Fernand Labrie Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
US5180711A (en) * 1990-06-14 1993-01-19 Applied Research Systems Ars Holding N.V. Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
US5413990A (en) * 1993-08-06 1995-05-09 Tap Pharmaceuticals Inc. N-terminus modified analogs of LHRH
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5677184A (en) * 1994-04-19 1997-10-14 Takeda Chemical Industries, Ltd. CHO cells that express human LH-RH receptor
US5843901A (en) * 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
US5691314A (en) 1996-03-18 1997-11-25 The Medical College Of Hampton Roads Adjunctive therapy

Also Published As

Publication number Publication date
EP0871468A1 (de) 1998-10-21
US5780435A (en) 1998-07-14
AU1141397A (en) 1997-07-14
DK0871468T3 (da) 2005-01-24
US6384017B1 (en) 2002-05-07
JP2000513326A (ja) 2000-10-10
AU730948B2 (en) 2001-03-22
CA2238993A1 (en) 1997-06-26
US6211153B1 (en) 2001-04-03
EP1297840A2 (de) 2003-04-02
US6180609B1 (en) 2001-01-30
EP1297840A3 (de) 2003-09-10
WO1997022357A1 (en) 1997-06-26
US6153586A (en) 2000-11-28
PT871468E (pt) 2005-02-28
US5843902A (en) 1998-12-01
JP4126094B2 (ja) 2008-07-30
ES2227622T3 (es) 2005-04-01
CA2238993C (en) 2004-10-12
DE69633405T2 (de) 2005-11-17
JP2006022118A (ja) 2006-01-26
ATE275962T1 (de) 2004-10-15
EP0871468B1 (de) 2004-09-15
HK1016087A1 (en) 1999-10-29

Similar Documents

Publication Publication Date Title
ATE275962T1 (de) Behandlung von prostatakrebs mit lhrh- antagonisten
Lanoue et al. Basal cell carcinoma: a comprehensive review of existing and emerging nonsurgical therapies
DE69022722D1 (de) Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
NZ285159A (en) Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
DK0595796T3 (da) Fremgangsmåde til behandling af androgen-relaterede sygdomme
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR9908592A (pt) Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
DE69426334T2 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
EP1348466A3 (de) Schmerzbehandlung mit Adenosin-Tetraphosphaten
WO2000040229A3 (en) Synergistic tumorcidal response induced by histamine
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
WO2000061141A3 (en) Methods and compositions for enhancing delivery of therapeutic agents to tissues
WO2004056971A3 (en) Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
Zaccheo et al. Effect of early treatment of prostate cancer with the 5α‐reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats
WO2003039466A3 (en) Method of treating estrogen responsive breast cancer
ID26965A (id) Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid
DE69430356T2 (de) Karzinostatisches Mittel für Hormontherapie, das Dienogest als wirksamer Bestandteil enthält
BR9607178A (pt) Antagonista de peptìdeo de hormÈnio estimulando alfa -melanócitos, processos para a inibição da atividade de hormÈnio estimulando alfa-melanócitos em um tecido ou célula que responde a hormÈnio estimulando alfa -melanócitos, para o clareamento da complexação de um animal e para o tratamento de melanoma maligno, composição farmacêutica, e, kit
NO20000007D0 (no) Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å oeke proteinkinase-B(PKB)- aktivitet
AU7551700A (en) Administration of gamma globulins to treat lymphoma
WO2023164704A3 (en) Hydrogel conductivity impacts skin dose from tumor treating fields
Pernot et al. IR 192 brachytherapy in the management of 147 T2NO oral tongue carcinoma treated with irradiation alone
RU95107493A (ru) Способ лечения опухолей паренхиматозных органов
WO1999060988A3 (en) Combination therapy for treatment of fiv infection

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings
8339 Ceased/non-payment of the annual fee